FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...
In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...
In this video interview following the 2026 DIA Global Annual Meeting, Jonathan Andrus, co-CEO of CRIO, explains why ...
Clinical trial sponsors are navigating a shifting landscape that includes both long-established life sciences companies ...
Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract
This article argues that improving financial outcomes—including more reliable revenue recognition—requires revisiting the ...
In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO ...
In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising ...
Insilico Medicine and SK Biopharmaceuticals entered an R&D collaboration on AI-enabled drug discovery in neuroimmune CNS ...
Traditional CRO contracting models create misalignment between effort, progress, and financial outcomes, driving revenue recognition risk and margin volatility, but shared performance contracts ...
Nature Medicine withdrew confidence in LungTIME-C01.1 after identifying substantial documentation discrepancies and unusual efficacy/safety patterns inconsistent with typical phase 3 ...
Understand how Syneos Health's FSP model differs from short-term staffing augmentation. Follow the logic of building a global talent hub to support continuity in clinical trials. Recognize the role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results